446 related articles for article (PubMed ID: 28198064)
1. Real-life practices for preventing venous thromboembolism in multiple myeloma patients: a cohort study from the French health insurance database.
Palmaro A; Rougé-Bugat ME; Gauthier M; Despas F; Moulis G; Lapeyre-Mestre M
Pharmacoepidemiol Drug Saf; 2017 May; 26(5):578-586. PubMed ID: 28198064
[TBL] [Abstract][Full Text] [Related]
2. Venous thromboembolism, thrombophilia, antithrombotic therapy, and pregnancy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).
Bates SM; Greer IA; Pabinger I; Sofaer S; Hirsh J
Chest; 2008 Jun; 133(6 Suppl):844S-886S. PubMed ID: 18574280
[TBL] [Abstract][Full Text] [Related]
3. MELISSE, a large multicentric observational study to determine risk factors of venous thromboembolism in patients with multiple myeloma treated with immunomodulatory drugs.
Leleu X; Rodon P; Hulin C; Daley L; Dauriac C; Hacini M; Decaux O; Eisemann JC; Fitoussi O; Lioure B; Voillat L; Slama B; Al Jijakli A; Benramdane R; Chaleteix C; Costello R; Thyss A; Mathiot C; Boyle E; Maloisel F; Stoppa AM; Kolb B; Michallet M; Lamblin A; Natta P; Facon T; Elalamy I; Fermand JP; Moreau P
Thromb Haemost; 2013 Oct; 110(4):844-51. PubMed ID: 23903204
[TBL] [Abstract][Full Text] [Related]
4. [Multiple myeloma and venous thrombosis. Which thromboprophylaxis should be given?].
de Moreuil C; Ianotto JC; Eveillard JR; Carrier M; Delluc A
Rev Med Interne; 2016 Jul; 37(7):473-9. PubMed ID: 26833146
[TBL] [Abstract][Full Text] [Related]
5. Thromboprophylaxis in multiple myeloma patients treated with lenalidomide - A systematic review.
Al-Ani F; Bermejo JM; Mateos MV; Louzada M
Thromb Res; 2016 May; 141():84-90. PubMed ID: 26986753
[TBL] [Abstract][Full Text] [Related]
6. Low venous thromboembolic risk with bortezomib in multiple myeloma and potential protective effect with thalidomide/lenalidomide-based therapy: review of data from phase 3 trials and studies of novel combination regimens.
Zangari M; Fink L; Zhan F; Tricot G
Clin Lymphoma Myeloma Leuk; 2011 Apr; 11(2):228-36. PubMed ID: 21575928
[TBL] [Abstract][Full Text] [Related]
7. A review of the venous thrombotic issues associated with multiple myeloma.
Fotiou D; Gerotziafas G; Kastritis E; Dimopoulos MA; Terpos E
Expert Rev Hematol; 2016 Jul; 9(7):695-706. PubMed ID: 27232265
[TBL] [Abstract][Full Text] [Related]
8. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma.
Palumbo A; Rajkumar SV; Dimopoulos MA; Richardson PG; San Miguel J; Barlogie B; Harousseau J; Zonder JA; Cavo M; Zangari M; Attal M; Belch A; Knop S; Joshua D; Sezer O; Ludwig H; Vesole D; Bladé J; Kyle R; Westin J; Weber D; Bringhen S; Niesvizky R; Waage A; von Lilienfeld-Toal M; Lonial S; Morgan GJ; Orlowski RZ; Shimizu K; Anderson KC; Boccadoro M; Durie BG; Sonneveld P; Hussein MA;
Leukemia; 2008 Feb; 22(2):414-23. PubMed ID: 18094721
[TBL] [Abstract][Full Text] [Related]
9. Identifying cancer drug regimens in French health insurance database: An application in multiple myeloma patients.
Palmaro A; Gauthier M; Despas F; Lapeyre-Mestre M
Pharmacoepidemiol Drug Saf; 2017 Dec; 26(12):1492-1499. PubMed ID: 28745019
[TBL] [Abstract][Full Text] [Related]
10. Comparison of pharmacologic prophylaxis in prevention of venous thromboembolism following total knee arthroplasty.
Richardson SS; Schairer WW; Sculco PK; Bostrom MP
Knee; 2019 Mar; 26(2):451-458. PubMed ID: 30700390
[TBL] [Abstract][Full Text] [Related]
11. Prophylaxis against venous thromboembolism in hospitalized medically ill patients.
Pendergraft T; Liu X; Edelsberg J; Phatak H; Vera-Llonch M; Liu LZ; Oster G
Circ Cardiovasc Qual Outcomes; 2013 Jan; 6(1):75-82. PubMed ID: 23300270
[TBL] [Abstract][Full Text] [Related]
12. Choosing the right heparin prophylaxis strategy in medical patients at risk for developing VTE: an evidence-based approach.
Harrington DW
Hosp Pract (1995); 2010 Nov; 38(4):18-28. PubMed ID: 21068523
[TBL] [Abstract][Full Text] [Related]
13. Prophylactic recombinant erythropoietin therapy and thalidomide are predictors of venous thromboembolism in patients with multiple myeloma: limited effectiveness of thromboprophylaxis.
Anaissie EJ; Coleman EA; Goodwin JA; Kennedy RL; Lockhart KD; Stewart CB; Coon SK; Bailey C; Barlogie B
Cancer; 2012 Jan; 118(2):549-57. PubMed ID: 21720994
[TBL] [Abstract][Full Text] [Related]
14. Effective prophylaxis of thromboembolic complications with low molecular weight heparin in relapsed multiple myeloma patients treated with lenalidomide and dexamethasone.
Klein U; Kosely F; Hillengass J; Hundemer M; Schmitt S; Neben K; Moehler T; Hegenbart U; Ho AD; Goldschmidt H
Ann Hematol; 2009 Jan; 88(1):67-71. PubMed ID: 18668241
[TBL] [Abstract][Full Text] [Related]
15. Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide.
Larocca A; Cavallo F; Bringhen S; Di Raimondo F; Falanga A; Evangelista A; Cavalli M; Stanevsky A; Corradini P; Pezzatti S; Patriarca F; Cavo M; Peccatori J; Catalano L; Carella AM; Cafro AM; Siniscalchi A; Crippa C; Petrucci MT; Yehuda DB; Beggiato E; Di Toritto TC; Boccadoro M; Nagler A; Palumbo A
Blood; 2012 Jan; 119(4):933-9; quiz 1093. PubMed ID: 21835953
[TBL] [Abstract][Full Text] [Related]
16. Thromboembolism incidence and prophylaxis during vaginal delivery hospitalizations.
Friedman AM; Ananth CV; Prendergast E; Chauhan SP; D'Alton ME; Wright JD
Am J Obstet Gynecol; 2015 Feb; 212(2):221.e1-12. PubMed ID: 25240092
[TBL] [Abstract][Full Text] [Related]
17. Safety of venous thromboembolism prophylaxis with fondaparinux in ischemic stroke.
Hackett CT; Ramanathan RS; Malhotra K; Quigley MR; Kelly KM; Tian M; Protetch J; Wong C; Wright DG; Tayal AH
Thromb Res; 2015 Feb; 135(2):249-54. PubMed ID: 25554497
[TBL] [Abstract][Full Text] [Related]
18. Venous thromboembolism prophylaxis and clinical consequences in medically ill patients.
Baser O; Liu X; Phatak H; Wang L; Mardekian J; Kawabata H; Petersel D; Hamilton M; Ramacciotti E
Am J Ther; 2013; 20(2):132-42. PubMed ID: 23466619
[TBL] [Abstract][Full Text] [Related]
19. Multiple myeloma, venous thromboembolism, and treatment-related risk of thrombosis.
Zamagni E; Brioli A; Tacchetti P; Zannetti B; Pantani L; Cavo M
Semin Thromb Hemost; 2011 Apr; 37(3):209-19. PubMed ID: 21455855
[TBL] [Abstract][Full Text] [Related]
20. [Thoughts about thromboembolic events prophylaxis in cancer patients].
Pikó B; Kremer IM; Rahoty P; Bassam A; Dimák S; Kis A; Csiffári M; Rus-Gal P; Szabó Z; Veréb B; Zsilak J
Magy Onkol; 2011 Sep; 55(3):164-9. PubMed ID: 21918741
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
